Glioblastoma (GBM) is an aggressive IDH wild-type tumor with recurrent molecular alterations; however, comprehensive genomic analyses of GBM arising in patients treated with TNF-α inhibitors are extremely limited. This evidence concerns the gene TNF and glioblastoma.